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Abstract 
Background: Designing novel therapeutic agents has been a critical challenge for HIV disease.  
Materials and Methods: In current study a DNA sequence which was encoded the Tat protein was synthesized and 
inserted in pET 28 vector. Vector was cloned in BL21-DE3 E. coli and cultured in TB media. After protein 
expression, recombinant Tat protein was purified by NTA affinity chromatography. The Tat purified protein 
efficiency and confirmed by SDS-PAGE and Western blot, respectively. We were immunized the camel against 
HIV-1 Tat recombinant protein to made a camelid antibody library. Total RNA was extracted from camel 
lymphocytes and VHH fragments synthesized and amplified using RT-PCR and Nested- PCR methods by special 
primers. 
Results: The 350- 450 bp VHH gene fragment was produced by RT-PCR and Nested- PCR and extracted from 
agarose gel 1%. Then gel extraction was performed and pure fragments were inserted in HEN-4 vector by T4 DNA 
ligase. 
Conclusion: The library can be applied for biopanning and isolation of nanobody against HIV-1 Tat Protein. 
Nanobody small size may be a useful drug for treatment of HIV disease because give them the potency of the 
recognizing the cryptic epitopes of tat and neutralized the virus. 
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The Human immunodeficiency virus (HIV) is 
caused the acquired immunodeficiency syndrome 
(AIDS). HIV type 1 (HIV-1) is one of types of this 
retroviral complex. There are many transactivatiors 
which regulate transcription of HIV-1 in cellular or 
viral manner. Tat is a protein which regulates and 
enhances the efficiency of transcription of the HIV 
dsDNA. Tat gene encodes Tat protein in HIV-1 (1). 
Tat represents for "Trans-Activator of Transcription” 
an constitutes of 86or 101 amino acids depending on 
the virus subtype (2, 3). TAR (Transactivation 
response element) an untranslatable sequence of all 
HIV RNAs which is located on 5’ region is necessary 
for mediation of Tat transactivation (4, 5).  TAR 
element prepares binding site for Tat in the nearside 
ofHIV-1 promoter (6). 
Sheikholeslami et al.                                                   Cloning, expression and library construction for HIV-1 Tat Protein                                                    
 Archives of Medical Laboratory Sciences 
8 
Tat mediated transcription needs interaction 
between Tat and Tat binding factors –small proteins-
which causes protein phosphorylation when some 
cellular proteins are attached to TAR region(7, 8). 
Tat acts as a transcription initialization factor (TIF) 
and increases the transcription elongation (9). Also, 
Tat plays a critical role in the HIV disease process. 
Tat protein is released by infected cells in culture 
media, and can be measured in the blood of HIV-1 
positive patients which is a profitable resort for 
surpassing the body's response (10). It has been 
showed that Tat protein is able to stimulate the 
expression of tumor necrosis factor 
α and ß , IL-10and IL-2 (11-13) which they 
may bean activator of expression and replication of 
HIV-1 gene (14, 15). Tat only inhibits PHA 
(phytohemagglutinin)-a mitogenic lectin-induced 
proliferation of primary human lymphocytes but also 
decrease the expression of MHC class I genes (16). 
Furthermore Tat can enhances the expression of 
cytokine transforming growth factor ß1 (TGF-ß1) 
which the potentially is an immunosuppresor agent 
(17). It is believed that HIV-1-infected cells have the 
ability of recognition of specific cytotoxic T 
lymphocytes and avoiding the immune surveillance 
(18, 19). 
Scientists have investigated the inhibition of 
Tat and suggested that some Tat antagonists might be 
useful in treatment of HIV infections (20, 21).The 
newly introduced treatment for HIV-1 infection is 
employing of nobodies. Nanobody is a single-domain 
antibody which is consisting of hyper variable 
domain (VHH) of heavy chain camel 
immunoglobulin. Like a whole antibody, it is able to 
bind selectively to a specific antigen. They weight 
11–15 kDa and can be produced naturally in Camelid 
such as camels and llamas. There have desired 
features like: physical stability, high tissue 
penetration, increased solubility, and low 
immunogenicity. Also nanobodies could be easily 
generated in multivalent forms by using short 
suitable peptide linkers (22). In this study we want to 
clone and express HIV-1 Tat Protein and injecting 




Ethics Statement. All used procedures in this study 
were approved by the Institutional Ethical Committee 
and Research Advisory Committee of Pasteur Institute 
of Iran based on National Specific Ethical Guidelines 
for Biomedical Research issued by Ministry of Health 
and Medicinal Education (MOHME) of Iran in 2005. 
Cloning and expression of Tat gene. First Tat-HIV 
gene was cloned on pET 28 vector and transformed to 
E. coli BL21-DE3 bacteria. For confirmation of 
cloning Tat gene containing vector was digested with 
NcoI and XhoI restriction enzymes.  
Analysis of protein Expression via SDS-PAGE and 
western blot. The transfected bacterium was 
incubated at 37°C with shaking speed 180rpm. Tat 
protein expression was investigated in different time 
points: 30 min. 1, 2, 3, 4, 24 hours. Different samples 
were gathered before and after protein induction to 
perform SDS-PAGE. The SDS-PAGE was done on 
15% (w/v) acrylamide bis acrylamide gel. To conduct 
western blot, the SDS-PAGE loaded proteins were 
transferred to nitrocellulose membrane (Sartorius, 
Germany) and detected by mouse monoclonal anti-6X 
His tag (Antibody 18184, Abcam, Cambridge, MA) as 
primary antibody. Next, the Peroxidase-conjugated 
goat anti-mouse immunoglobulin (Dako) as secondary 
antibody was added. Finally, diamino benzoic acid 
(DAB, Amersham Bioscience, and Piscataway, NJ, 
USA) were applied as the chromogenic substrates. 
Tat purification. E. coli BL21-DE3 cells was 
transformed with Recombinant Tat expression vector 
And induced to express protein at mid-log phase 
(OD600=0.5) using 1 mM IPTG. His-tagged protein 
was purified under native condition by applying Ni-
NTA affinity chromatography column (Qiagen, USA), 
based on the manufacturer’s instructions. Briefly, 
transformed E. coli BL21 (DE3) cells were gently 
vortexed and suspended in lysis buffer (50mM 
NaH2PO4. 300mM NaCl, 10mM imidazole, pH 8). To 
clarify the supernatant, the lysate centrifuged for 10 
min at 6000×g and loaded onto a Ni-NTA column. 
Finally, after washing steps, the attached protein was 
eluted using 300mM imidazole and was loaded on 
SDS-PAGE to check the quality of protein 
purification. 
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Immunization procedure. A 4-year-old female 
Camelus dromedarius was immunized by 
recombinant protein as specific antigen.Onemg of 
purified HIV-1 Tat protein mixed with 1 ml of 
Frund’s complete adjuvant. Four injections were 
done by 1 mg of antigen with 1 ml Frund’s 
incomplete adjuvant every 14 days.  
Lymphocyte isolation. After fifth injection of 
antigen blood sample was taken on a sterile 50mL 
Tube. Lymphocytes were isolated using ficole 
gradient sedimentation by centrifuging and 
lymphocyte layer separated from other layers. 
Purified cells were washed through PBS, count and 
to 106lymphocyteper cryotube was stored at -70˚C. 
RNA Extraction, cDNA synthesis. RNA extraction 
from lymphocytes was performed by EZ-10 RNA 
Mini-Preps Kits from Bio Basic CANADA INC. 
Extracted RNA can be store at -70˚C. Extracted RNA 
was immediately applied for cDNA synthesis by a 
cDNA preparing kit from Fermentas Company and 
can be stored at -20˚C.  
PCRs and Library production. Using cDNA as 
template and CALL001 and C1LL002 specific 
primers, the polymerase chain reaction performed by 
master mix solution of Qiagene Company. Produced 
VH fragments were observed on agarose gel 
electrophoresis. Products were purified by Qiagene 
extraction kit to apply for nested PCR. Nested PCR 
was performed using P38 and AGE primers to 
produce VHH fragments which purified by gel 
extraction kit from agarose gel 1%. VHH fragments 
were extracted using Qiagene extraction kit and 
applied to a ligation reaction with pHEN-4 vector to 
infect TG1 E. coli. 
Results 
Cloning and expression of Tat. After cloning of the 
Tat gene, enzymatic digestion was performed on 
pET28a vector using NcoI and XhoI restriction 
enzymes (Fig. 1).Different samples were gathered 
transfected bacteria before and after protein 
expression induction to perform SDS-PAGE (Figure 
2). 
 The 14-17 kDa protein band was observed on 15% 
gel.  
Purification of recombinant HIV-1 Tat protein.  
Output of Ni-NTA column after washing with elution 
buffer was gathered and applied for 15% SDS-PAGE. 
Tat protein came out from the column after washing 
with elution buffer which was concluded 300mM 
imidazole. 
PCR amplification. VH fragment amplified with 
CALL001 and C1LL002 primers. We were observed 
 
Figure 1. Enzymatic Digestion of pET28a vector using NcoI and 
XhoI restriction enzymes. From left to right: 2700 bp fragment 
belongs to digested vector and 350 bp fragment belongs to Tat 
gene. Second lane belongs to undigested recombinant vector. Last 
lane is DNA ladder. 
 
 
Figure 2. The samples have equal concentration of proteins on the 
SDS-PAGE 15%. Protein marker is the first lane. 2, 3, 4, 5, 6 and 7 
are samples that were induced after 24, 4, 3, 2,1 hoursand30 minutes 
after induction, respectively. 
 
 
Figure 3. To do western blot analysis, samples were loaded on 
SDS-PAGE and transferred onto nitrocellulose membrane and after 
adding primary and secondary antibodies was visualized by DAB.  
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two sharp bands of fragments upon gel about 900 and 
700bp. The 700bp bands belong to VH. In order to 
produce VHH fragments nested-PCR was performed 
by P38 and AGE primers. The amplified fragment 
belongs to VHH gene observed 350bp.  
Discussion 
AIDS is acritical health problem which has 
affected the life of millions of people on the world. 
Tat, induce virus neutralizing antibody that 
makes it a potential immunogenic for nanobody 
production. Anti-Tat monoclonal antibody (7G12) can 
be neutralize the variants of Tat proteins (23).  
As a new strategy we want to inhibit HIV 
replication by 11-15 KDa nanobody because 
conventional antibody not able to penetrate in hidden 
epitopes and cannot crossed blood brain barrier (24). 
Tat has outstanding effect on replication and 
pathogenesis of HIV (18). Tat is the one of the first 
viral proteins that is cloned and expressed as a 
recombinant protein (19). 
Some scientists have shown that camel 
nanobodies are capable to neutralize HIV-1 (25). 
Forsman was produced two nanobodies against the 
Env antigen of HIV-1 in 2008 but the antigen is not 
conserved in all species and doesn’t has neutralization 
effect on  broad but she implies that the VHH is able 
to neutralize a variety range of subtypes HIV-1 (26, 
27). In 2010 Vercruysse produced an intrabody against 
Rev Protein of HIV-a regulatory protein that join 
mRNAs structure together and causes the nucleus to 
be let out to the cytoplasm-was disrupted the 
proliferation of HIV-1 by preventing the assembling of 
proteins by binding of the Lys-20 and Tyr-23 subunits 
in the N-Terminal Therefore Rev has a crucial role in 
virus replication (28). Our result indicates that Tat 
protein of HIV was cloned, expressed and purified 
successfully. After camel immunization and bleeding, 
lymphocytes isolated and RNA extracted, cDNA was 
synthesized and DNA amplification carried out by 
PCR. Then, 600 and 350 bp fragments are prepared 
and ligation conducted to generate a phage library. In 
future studies, we are going to carry out bio panning 
and isolate nanobody to and evaluate its therapeutic 
effects on HIV virus replication. 
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